Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Study to investigate the bioequivalence between 10 mg tablets (test drug) and 10 mg capsules (reference drug) of meloxicam (UHAC 62 XX) in fasted state.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| UHAC 62 XX tablet | Experimental |
| |
| UHAC 62 XX capsule | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| UHAC 62 XX tablet | Drug |
| ||
| UHAC 62 XX capsule |
| Measure | Description | Time Frame |
|---|---|---|
| Cmax (Maximum observed concentration of the analyte in plasma) | up to 60 hours after drug administration | |
| AUC 0-60hr (Area under the concentration time curve of the analyte in plasma from zero time to 60 hours) | up to 60 hours after drug administration |
| Measure | Description | Time Frame |
|---|---|---|
| Tmax (Time to reach Cmax) | up to 60 hours after drug administration | |
| t1/2 ( Terminal half-life of the analyte in plasma) | up to 60 hours after drug administration | |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
|
| AUC 0-infinity (Area under the concentration time curve of the analyte in plasma from zero time to infinity) |
| up to 60 hours after drug administration |
| MRT 0-infinity (Mean residence time of the analyte molecules in the body from zero time to infinity) | up to 60 hours after drug administration |
| Number of patients with adverse events | up to 20 days after final drug administration |